Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma
The European Journal of Health Economics · 2025
DOI: 10.1007/s10198-024-01729-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The European Journal of Health Economics, 2025. Verfasst von Simone Seyringer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Psychiatry, Psychotherapy and Psychosomatic Medicine,University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck,…. Hauptthemen laut MEDLINE: Glioblastoma, Quality of Life, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Organisation for Research and Treatment of Cancer, University of Innsbruck and Medical University of Innsbruck.
Abstract (Originalsprache)
Introduction
Many health economic evaluations rely on the validity of the utility measurement for health-related quality of life (HRQoL). While generic utility measures perform well in HRQoL assessments of many diseases and patient populations, appropriateness for cancer-specific disease burdens needs attention and condition-specific measures could be a viable option. This study assessed the clinical validity of the cancer-specific EORTC QLU-C10D, a utility scoring algorithm for the EORTC QLQ-C30, in patients with glioblastoma. We expect the EORTC QLU-C10D to be sensitive and responsive in glioblastoma patients. Furthermore, we compared its statistical efficiency with the generic utility measure EQ-5D-3L.
Methods
We used data from a multi-center randomized controlled trial (NCT00689221) with patients from 146 study sites in 25 countries. Both, the QLQ-C30 and the EQ-5D-3L, had been administered at seven assessment points together. Utilities of both measures were calculated for four country value set (Australia, Canada, UK, USA). Ceiling effects, agreement (Bland–Altman plots (BA), intra-class correlation (ICC)), were calculated to analyze construct validity. Sensitivity to known-groups (performance status; global health) and responsiveness to changes (progressive vs. non-progressive; stable vs. improved or deteriorated HRQoL) were investigated for clinical validity. Relative Efficiency (RE) was calculated to compare statistical efficiency of both utility measures.
Results
435 patients were included at baseline and six subsequent time points (median timeframe 497 days). QLU-C10D country value set showed negligible ceiling effects (< 6.7%) and high agreement with EQ-5D-3L (ICC > 0.750). BA indicated that differences between both utility measures increased with deteriorating health states. While the QLU-C10D was more sensitive to global health groups (RE > 1.2), the EQ-5D-3L was more sensitive to performance status groups (RE < 0.7) than the other utility measure. Statistical efficiency to detect differences between change groups and within HRQoL deterioration group (RE > 1.4) favored QLU-C10D in 18 of 24 (75%) and 20 of 24 (83%) comparisons with the EQ-5D-3L respectively. Responsiveness to overall HRQoL change (RE > 3.4) also favored the QLU-C10D.
Conclusion
Our results indicate that the QLU-C10D is a valid utility measure to assess HRQoL in patients with glioblastoma. This facilitates the investigation of HRQoL profiles and utilities in this patient population by administering a single questionnaire, the EORTC QLQ-C30. Efficiency analyses point to higher statistical power of the QLU-C10D compared to the EQ-5D-3L.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department for Psychiatry, Psychotherapy and Psychosomatic Medicine,University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Social Psychology, Personnel Development and Adult Education, Johannes Kepler University Linz, Linz, Austria.
- Department of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
- European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
- School of Psychology, University of Sydney, Camperdown, NSW, Australia.
- School of Population Health, Curtin University, Perth, WA, Australia.
Förderung
- European Organisation for Research and Treatment of Cancer
- University of Innsbruck and Medical University of Innsbruck
Zitieren
APA
Seyringer, S., Pilz, M. J., Bottomley, A., King, M. T., Norman, R., Gamper, E. M., & EORTC Quality of Life Group (2025). Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01729-4
Vancouver
Seyringer S, Pilz MJ, Bottomley A, King MT, Norman R, Gamper EM, et al. Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma. The European Journal of Health Economics. 2025. doi:10.1007/s10198-024-01729-4
BibTeX
@article{Seyringer2025,
author = {Seyringer, Simone and Pilz, Micha J and Bottomley, Andrew and King, Madeleine T and Norman, Richard and Gamper, Eva M and EORTC Quality of Life Group, EORTC Quality of Life Group},
title = {Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma},
journal = {The European Journal of Health Economics},
year = {2025},
doi = {10.1007/s10198-024-01729-4}
}
EUVIMED